Evaluating color discrimination in patients with neurodegenerative disorders
A Registered Observational Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.
This study is testing how well people with Alzheimer's and mild cognitive impairment can tell colors apart compared to others their age to learn more about how these conditions affect vision and thinking.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 30 Years to 80 Years |
| Sex | All |
| Sponsor | Fujian Medical University Union Hospital Academic / other |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT05639140 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess color discrimination deficits in patients with Alzheimer's disease and mild cognitive impairment using the Farnsworth-Munsell 100 hue test. The study compares the results of these tests between affected individuals and age-matched control subjects to better understand the pathophysiology of color discrimination dysfunction. Additionally, it explores the relationship between visual test outcomes and cognitive performance. The research involves extensive clinical and neuropsychological examinations conducted by specialists.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with Alzheimer's disease or mild cognitive impairment who meet specific clinical criteria.
Not a fit: Patients with noncompensated somatic illnesses, psychiatric disorders, color blindness, or significant ophthalmological issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of visual deficits in neurodegenerative disorders, potentially leading to improved diagnostic and therapeutic strategies.
How similar studies have performed: While color discrimination deficits have been noted in neurodegenerative conditions, this specific approach using the Farnsworth-Munsell test is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients underwent extensive clinical examination including thorough neurological and somatic examination by a specialized neurologist or geriatrician and extensive neuropsychological examination by a trained psychologist. AD was diagnosed according to the NINCDS-ADRDA criteria. Exclusion Criteria: * We excluded individuals with noncompensated somatic illnesses, a history of a psychiatric disorder, color blindness, ophthalmological pathology, severe cranial trauma, focal neurological signs or magnetic resonance imaging examinations suggestive of cerebrovascular disturbances.
Where this trial is running
Fuzhou, Fujian
- Fujian Medical University Union Hospital — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Xiaodong Pan, Doctor
- Email: pxd77316@163.com
- Phone: 0591-86218341
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.